Development of novel CD22 nanobodies
By developing nanobodies with specific sequences, the shortcomings of CD22 monoclonal antibodies in terms of molecular weight, immunogenicity, and stability have been overcome, achieving highly effective targeted therapy for B-cell-related diseases.
Patent Information
- Application Number
- PCT/CN2024/095460
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-29
- Filing Date
- 2024-05-27
- Publication Date
- 2024-12-05
AI Technical Summary
Existing CD22 monoclonal antibodies suffer from problems such as large molecular weight, strong immunogenicity, insufficient tissue penetration and stability, making it difficult to effectively target and treat B-cell-related diseases.
A nanobody targeting CD22 was developed. Using a specific VHH chain complementarity-determining region (CDR) amino acid sequence and framework region (FR), combined with a polynucleotide expression vector and a host cell system, the anti-CD22 nanobody was prepared and purified for use in constructing immunoconjugates for targeted therapy.
Nanobodies possess high affinity, small molecular weight, rapid tissue penetration, and high stability. They can recognize hidden antigenic epitopes that monoclonal antibodies cannot recognize, thereby reducing immunogenicity and improving therapeutic efficacy.
Smart Images

Figure PCTCN2024095460-FTAPPB-I100001 
Figure PCTCN2024095460-FTAPPB-I100002 
Figure PCTCN2024095460-FTAPPB-I100003
Abstract
Description
Development of a novel CD22 nanobody Technical Field
[0001] The present invention relates to the field of biomedicine. Specifically, the present invention relates to nano antibodies targeting CD22. Background Art
[0002] CD22 is a myeloid cell differentiation antigen and a member of the sialic acid-binding immunoglobulin family. It is mainly expressed intracellularly in the early stages of B cell development, transferred to the extracellular space as B cells mature, and is highly expressed in most B cell malignancies.
[0003] CD22 is a promising anti-tumor target. However, most current CD22 antibody drugs are monoclonal antibodies. Monoclonal antibodies may have issues such as large molecular weight and immunogenicity, and their tissue penetration, solubility, and stability need to be improved.
[0004] Therefore, there is a need in the art to develop a new type of nanobody targeting CD22.
[0005] Summary of the Invention
[0006] The purpose of the present invention is to provide a nanobody targeting CD22 and its application.
[0007] In the first aspect of the present invention, an anti-CD22 nanobody is provided, wherein the amino acid sequence of the complementarity determining region (CDR) of the VHH chain of the anti-CD22 nanobody is selected from the following group:
[0008] (1) CDR1 shown in SEQ ID NO: 13, CDR2 shown in SEQ ID NO: 14, and CDR3 shown in SEQ ID NO: 15;
[0009] (2) CDR1 shown in SEQ ID NO: 6, CDR2 shown in SEQ ID NO: 9, and CDR3 shown in SEQ ID NO: 10;
[0010] (3) CDR1 shown in SEQ ID NO: 6, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 12;
[0011] (4) CDR1 shown in SEQ ID NO: 6, CDR2 shown in SEQ ID NO: 7, and CDR3 shown in SEQ ID NO: 8; and
[0012] (5) CDR1 shown in SEQ ID NO: 6, CDR2 shown in SEQ ID NO: 7, and CDR3 shown in SEQ ID NO: 16.
[0013] In another preferred embodiment, the anti-CD22 nanobody can specifically bind to CD22.
[0014] In another preferred embodiment, any one of the amino acid sequences further comprises a derivative sequence that is optionally added, deleted, modified and / or substituted with at least one (such as 1-3, preferably 1-2, more preferably 1) amino acid and can retain the ability to specifically bind to CD22.
[0015] In another preferred embodiment, the anti-CD22 nanobody further includes a framework region FR.
[0016] In another preferred embodiment, the CDR1, CDR2 and CDR3 are separated by the framework regions FR1, FR2, FR3 and FR4 of the VHH chain.
[0017] In another preferred embodiment, the framework regions FR1, FR2, FR3 and FR4 have sequences derived from SEQ ID NO: 1, 2, 3, 4 or 5.
[0018] In another preferred embodiment, the VHH chain amino acid sequence of the anti-CD22 nanobody has a sequence identity of ≥85%, ≥90%, ≥95%, ≥96%, ≥97%, ≥98%, or ≥99% to the amino acid sequence shown in SEQ ID NO: 1, 2, 3, 4 or 5.
[0019] In another preferred embodiment, the VHH chain of the anti-CD22 nanobody has the amino acid sequence shown in SEQ ID NO: 1, 2, 3, 4 or 5.
[0020] In another preferred embodiment, the anti-CD22 nanobody includes monomers, bivalent bodies (bivalent antibodies), and / or multivalent antibodies.
[0021] In another preferred embodiment, the anti-CD22 nanobody includes a humanized antibody, a camel-derived antibody, or a chimeric antibody.
[0022] In a second aspect of the present invention, an anti-CD22 chimeric antigen receptor (CAR) is provided, wherein the chimeric antigen receptor comprises an antigen binding domain, and the antigen binding domain comprises one or more VHH chains of the anti-CD22 nanobody as described in the first aspect of the present invention.
[0023] In another preferred embodiment, the amino acid sequence of the VHH chain of the anti-CD22 nanobody is selected from the sequence shown in SEQ ID NO: 1, 2, 3, 4 or 5.
[0024] In the third aspect of the present invention, a polynucleotide is provided, which encodes a protein selected from the following group: the anti-CD22 nanobody as described in the first aspect of the present invention, or the chimeric antigen receptor as described in the second aspect of the present invention.
[0025] In the fourth aspect of the present invention, an expression vector is provided, wherein the expression vector contains the polynucleotide according to the third aspect of the present invention.
[0026] In another preferred embodiment, the expression vector is selected from the following group: DNA, RNA, viral vector, plasmid, transposon, other gene transfer systems, or a combination thereof.
[0027] In another preferred embodiment, the expression vector is a lentiviral vector.
[0028] In the fifth aspect of the present invention, a host cell is provided. The host cell contains the expression vector according to the fourth aspect of the present invention, or the polynucleotide according to the third aspect of the present invention is integrated into its genome.
[0029] In another preferred embodiment, the host cell includes a prokaryotic cell or a eukaryotic cell.
[0030] In another preferred embodiment, the host cell is selected from the group consisting of Escherichia coli, yeast cells, and mammalian cells.
[0031] In a sixth aspect of the present invention, there is provided a method for producing an anti-CD22 nanobody, comprising the steps of:
[0032] (a) culturing the host cell as described in the fifth aspect of the invention under conditions suitable for the production of nanobodies, thereby obtaining a culture containing the anti-CD22 nanobody;
[0033] (b) isolating and / or recovering said anti-CD22 Nanobody from said culture; and
[0034] (c) Optionally, purifying and / or modifying the anti-CD22 Nanobody obtained in step (b).
[0035] In a seventh aspect of the present invention, an immunoconjugate is provided, comprising:
[0036] (a) an anti-CD22 Nanobody as described in the first aspect of the invention, or a chimeric antigen receptor as described in the second aspect of the invention; and
[0037] (b) a conjugated moiety selected from the group consisting of a detectable label, a drug, an enzyme, a cytokine, a nanoparticle, a viral coat protein or a VLP, or a combination thereof.
[0038] In another preferred embodiment, the radioactive nuclides include:
[0039] (i) a diagnostic isotope selected from the group consisting of Tc-99m, Ga-68, F-18, I-123, I-125, I-131, In-111, Ga-67, Cu-64, Zr-89, C-11, Lu-177, Re-188, or a combination thereof; and / or
[0040] (ii) therapeutic isotopes, wherein the therapeutic isotopes are selected from the group consisting of Lu-177, Y-90, Ac-225, As-211, Bi-212, Bi-213, Cs-137, Cr-51, Co-60, Dy-165, Er-169, Fm-255, Au-198, Ho-166, I-125, I-131, Ir-192, Fe-59, Pb-212, Mo-99, Pd-103, P-32, K-42, Re-186, Re-188, Sm-153, Ra223, Ru-106, Na24, Sr89, Tb-149, Th-227, Xe-133, Yb-169, Yb-177, or a combination thereof.
[0041] In another preferred embodiment, the coupling moiety is a detectable label.
[0042] In another preferred embodiment, the detectable marker includes radionuclides and gold nanoparticles / nanorods.
[0043] In another preferred embodiment, the coupling portion is selected from the following group: fluorescent or luminescent markers, radioactive markers, MRI (magnetic resonance imaging) or CT (computer tomography) contrast agents, or enzymes capable of producing detectable products, radionuclides, biotoxins, cytokines (such as IL-2, etc.), antibodies, antibody Fc fragments, antibody scFv fragments, gold nanoparticles / nanorods, viral particles, liposomes, nanomagnetic particles, prodrug-activating enzymes (for example, DT-diaphorase (DTD) or biphenyl hydrolase-like protein (BPHL)) or any form of nanoparticles.
[0044] In another preferred embodiment, the immunoconjugate contains: a multivalent (eg, bivalent) VHH chain of the anti-CD22 nanobody as described in the first aspect of the present invention.
[0045] In another preferred embodiment, the multivalency means that the amino acid sequence of the immunoconjugate contains multiple VHH chains of the anti-CD22 nanobody as described in the first aspect of the present invention.
[0046] In an eighth aspect of the present invention, there is provided a use of the anti-CD22 nanobody as described in the first aspect of the present invention, or the chimeric antigen receptor as described in the second aspect of the present invention, or the expression vector as described in the fourth aspect of the present invention, or the host cell as described in the fifth aspect of the present invention, or the immunoconjugate as described in the seventh aspect of the present invention, for preparing:
[0047] (1) Drugs for preventing and / or treating CD22-related diseases;
[0048] (2) Reagents for detecting CD22.
[0049] In another preferred embodiment, the CD22-related diseases include: cancer and autoimmune diseases.
[0050] In another preferred embodiment, the cancer or tumor is selected from the group consisting of hematological tumors, lymphomas, solid tumors, or a combination thereof.
[0051] In another preferred embodiment, the blood tumor is selected from the group consisting of acute myeloid leukemia (AML), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), or a combination thereof.
[0052] In another preferred embodiment, the lymphoma is selected from the following group: Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), Burkitt lymphoma (BL) and other complex B-cell non-Hodgkin lymphomas.
[0053] In another preferred embodiment, the solid tumor is selected from the following group: gastric cancer, gastric cancer peritoneal metastasis, liver cancer, kidney tumor, lung cancer, small intestine cancer, bone cancer, prostate cancer, colorectal cancer, breast cancer, large intestine cancer, cervical cancer, ovarian cancer, lymphoma, nasopharyngeal carcinoma, adrenal tumor, bladder tumor, non-small cell lung cancer (NSCLC), brain glioma, endometrial cancer, testicular cancer, colorectal cancer, urinary tract tumor, thyroid cancer, or a combination thereof.
[0054] In another preferred embodiment, the CD22-related disease is B-acute lymphoblastic leukemia (B-ALL), B-cell lymphoma, or a combination thereof.
[0055] In another preferred embodiment, the subject of administration of the drug is a human or a non-human mammal (such as a rodent).
[0056] In a ninth aspect of the present invention, a pharmaceutical composition is provided, comprising:
[0057] (i) the anti-CD22 Nanobody as described in the first aspect of the invention, or the chimeric antigen receptor as described in the second aspect of the invention, or the vector as described in the fourth aspect of the invention, or the host cell as described in the fifth aspect of the invention, or the immunoconjugate as described in the seventh aspect of the invention; and
[0058] (ii) a pharmaceutically acceptable carrier.
[0059] In the tenth aspect of the present invention, a method for preventing and / or treating CD22-related diseases is provided, the method comprising administering to a subject in need thereof the anti-CD22 nanobody as described in the first aspect of the present invention, or the chimeric antigen receptor as described in the second aspect of the present invention, or the vector as described in the fourth aspect of the present invention, or the host cell as described in the fifth aspect of the present invention, or the immunoconjugate as described in the seventh aspect of the present invention.
[0060] In another preferred embodiment, the subject includes mammals, such as humans.
[0061] In another preferred embodiment, the CD22-related disease includes cancer or autoimmune disease.
[0062] In an eleventh aspect of the present invention, a method for diagnosing a CD22-related disease is provided, comprising the steps of:
[0063] (i) obtaining a sample from a diagnostic subject, and contacting the sample with the anti-CD22 Nanobody as described in the first aspect of the present invention, or the immunoconjugate as described in the seventh aspect of the present invention; and
[0064] (ii) detecting whether an antigen-antibody complex is formed, wherein the formation of the complex indicates that the subject suffers from a CD22-related disease.
[0065] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS
[0066] The following drawings are used to illustrate specific embodiments of the present invention and are not used to limit the scope of the present invention defined by the claims.
[0067] FIG1 shows a schematic diagram of the structure of a recombinant antibody expression vector.
[0068] FIG2 shows the results of peripheral blood PBMC sorting after immunization of llama with CD22.
[0069] Figure 3 shows the flow cytometry results after expression of the nanoantibodies constructed by the single B cell screening method.
[0070] Figure 4 shows the flow cytometry results after expression of the nanobodies constructed using the yeast display library method. DETAILED DESCRIPTION
[0071] After extensive and intensive research and extensive screening, the present inventors have obtained multiple anti-CD22 Nanobodies. Specifically, the present inventors immunized camels with CD22 antigen protein and, using single B cell sorting and yeast display libraries, obtained CD22-specific Nanobody genes. Experimental results demonstrated that the anti-CD22 Nanobodies of the present invention can specifically bind to CD22 with high affinity. This is the basis for the present invention.
[0072] the term
[0073] As used herein, the terms "antibody of the present invention", "anti-CD22 nanobody of the present invention", and "anti-CD22 nanobody" have the same meaning and are used interchangeably, all referring to antibodies that specifically recognize and bind to CD22.
[0074] Antibody
[0075] As used herein, the terms "antibody" or "immunoglobulin" are heterotetrameric glycoproteins of approximately 150,000 daltons with identical structural features, consisting of two identical light chains (L) and two identical heavy chains (H). Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide bonds varies between heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bonds. Each heavy chain has a variable region (VH) at one end, followed by multiple constant regions. Each light chain has a variable region (VL) at one end and a constant region at the other end; the constant region of the light chain is opposite the first constant region of the heavy chain, and the variable region of the light chain is opposite the variable region of the heavy chain. Specific amino acid residues form an interface between the variable regions of the light and heavy chains.
[0076] As used herein, the terms "single-domain antibody (sdAb)", "VHH", and "nanobody" have the same meaning and are used interchangeably. They refer to the construction of a single-domain antibody (VHH) consisting solely of a single heavy chain variable region by cloning the variable region of an antibody heavy chain. This is the smallest fully functional antigen-binding fragment. Typically, antibodies naturally lacking the light chain and heavy chain constant region 1 (CH1) are first obtained, and then the variable region of the antibody heavy chain is cloned to construct a single-domain antibody (VHH) consisting solely of a single heavy chain variable region.
[0077] As used herein, the term "variable" refers to certain parts of the variable region in an antibody that are different in sequence, which form the binding and specificity of various specific antibodies to their specific antigens. However, variability is not evenly distributed throughout the entire antibody variable region. It is concentrated in three segments called complementary determining regions (CDRs) or hypervariable regions in the light and heavy chain variable regions. The more conservative parts of the variable region are called framework regions (FRs). The variable regions of natural heavy and light chains each contain four FR regions, which are generally in a β-folded configuration, connected by three CDRs that form a connecting loop, and in some cases can form a partial β-folded structure. The CDRs in each chain are closely together through the FR region and form the antigen-binding site of the antibody together with the CDRs of the other chain (see Kabat et al., NIH Publ. No. 91-3242, Volume 1, pages 647-669 (1991)). The constant regions do not directly participate in the binding of the antibody to the antigen, but they exhibit different effector functions, such as participating in the antibody-dependent cytotoxicity of the antibody.
[0078] As known to those skilled in the art, immunoconjugates and fusion expression products include conjugates formed by binding of drugs, toxins, cytokines, radionuclides, enzymes, and other diagnostic or therapeutic molecules to the antibodies of the present invention or their fragments. The present invention also includes cell surface markers or antigens bound to the Nanobodies or their fragments directed against CD22.
[0079] As used herein, the terms "heavy chain variable region" and "VH" are used interchangeably.
[0080] As used herein, the terms "variable region" and "complementarity determining region (CDR)" are used interchangeably.
[0081] In a preferred embodiment of the present invention, the heavy chain variable region of the antibody includes three complementarity determining regions CDR1, CDR2, and CDR3.
[0082] In a preferred embodiment of the present invention, the heavy chain of the antibody includes the above-mentioned heavy chain variable region and heavy chain constant region.
[0083] The present invention also provides other proteins or fusion expression products comprising the antibodies of the present invention. Specifically, the present invention includes any protein or protein conjugate and fusion expression product (i.e., immunoconjugate and fusion expression product) comprising a heavy chain containing a variable region, as long as the variable region is identical to or at least 90% homologous to the heavy chain variable region of the antibodies of the present invention, preferably at least 95% homologous.
[0084] The terms "specific binding", "selective binding", "selectively binds" and "specifically binds" refer to the binding of an antibody to a predetermined epitope on an antigen. -7 M, for example, less than approximately 10 -8 M, 10 -9 M or l0 -10 Binds with an affinity (KD) of M or less.
[0085] The present invention includes not only complete antibodies, but also fragments of antibodies with immunological activity or fusion proteins formed by antibodies and other sequences. Therefore, the present invention also includes fragments, derivatives and analogs of the antibodies.
[0086] As used herein, the terms "fragment," "derivative," and "analog" refer to polypeptides that substantially retain the same biological function or activity as the antibodies of the present invention. A polypeptide fragment, derivative, or analog of the present invention may be (i) a polypeptide having one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) substituted, where such substituted amino acid residues may or may not be encoded by the genetic code, or (ii) a polypeptide having a substituent group in one or more amino acid residues, or (iii) a polypeptide formed by fusion of a mature polypeptide with another compound (e.g., a compound that extends the half-life of the polypeptide, such as polyethylene glycol), or (iv) a polypeptide formed by fusion of an additional amino acid sequence to the polypeptide sequence (e.g., a leader sequence or secretory sequence, or a sequence or proprotein sequence used to purify the polypeptide, or a fusion protein formed with a 6His tag). Based on the teachings herein, these fragments, derivatives, and analogs are well known to those skilled in the art.
[0087] The antibodies of the present invention refer to polypeptides that have CD22 protein binding activity and include the above-mentioned CDR regions. The term also includes variant forms of polypeptides that include the above-mentioned CDR regions and have the same function as the antibodies of the present invention. These variant forms include (but are not limited to): deletion, insertion and / or substitution of one or more (usually 1-50, preferably 1-30, more preferably 1-20, and most preferably 1-10) amino acids, and addition of one or more (usually within 20, preferably within 10, and more preferably within 5) amino acids to the C-terminus and / or N-terminus. For example, in the art, substitution with amino acids with similar or similar properties generally does not alter the function of the protein. For another example, addition of one or more amino acids to the C-terminus and / or N-terminus generally does not alter the function of the protein. The term also includes active fragments and active derivatives of the antibodies of the present invention.
[0088] Variant forms of the polypeptide include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, proteins encoded by DNA that can hybridize with the encoding DNA of the antibody of the present invention under high or low stringency conditions, and polypeptides or proteins obtained using antiserum against the antibody of the present invention.
[0089] The present invention also provides other polypeptides, such as fusion proteins comprising antibodies or fragments thereof. In addition to substantially full-length polypeptides, the present invention also encompasses fragments of the antibodies of the present invention. Typically, the fragments have at least about 50 contiguous amino acids of the antibodies of the present invention, more preferably at least about 80 contiguous amino acids, and most preferably at least about 100 contiguous amino acids.
[0090] In the present invention, "conservative variants of the antibodies of the present invention" refer to polypeptides in which no more than 10, preferably no more than 8, more preferably no more than 5, and most preferably no more than 3 amino acids are replaced with amino acids having similar or similar properties, compared to the amino acid sequence of the antibodies of the present invention. These conservative variant polypeptides are preferably generated by making amino acid substitutions according to Table A.
[0091] Table A
[0092] The invention also provides polynucleotide molecules encoding the above-mentioned antibodies, fragments thereof, or fusion proteins thereof. The polynucleotides of the present invention may be in the form of DNA or RNA. DNA forms include cDNA, genomic DNA, or synthetic DNA. DNA may be single-stranded or double-stranded. DNA may be a coding strand or a non-coding strand.
[0093] The polynucleotide encoding the mature polypeptide of the present invention includes: a coding sequence encoding only the mature polypeptide; a coding sequence of the mature polypeptide and various additional coding sequences; a coding sequence of the mature polypeptide (and optional additional coding sequences) and non-coding sequences.
[0094] The term "polynucleotide encoding a polypeptide" may include a polynucleotide encoding the polypeptide, or may also include additional coding and / or non-coding sequences.
[0095] The present invention also relates to polynucleotides that hybridize to the above-mentioned sequences and have at least 50%, preferably at least 70%, and more preferably at least 80% identity between the two sequences. The present invention particularly relates to polynucleotides that hybridize to the polynucleotides of the present invention under stringent conditions. In the present invention, "stringent conditions" refer to: (1) hybridization and elution at relatively low ionic strength and relatively high temperature, such as 0.2×SSC, 0.1% SDS, 60°C; or (2) the addition of a denaturing agent during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Ficoll, 42°C; or (3) hybridization occurs only when the identity between the two sequences is at least 90%, more preferably at least 95%. Furthermore, the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide.
[0096] The full-length nucleotide sequence of the antibody of the present invention or its fragments can generally be obtained by PCR amplification, recombinant methods, or artificial synthesis methods. One feasible method is to synthesize the relevant sequence by artificial synthesis, especially when the fragment length is relatively short. Generally, by first synthesizing multiple small fragments and then ligating them, very long fragments of sequence can be obtained. In addition, the coding sequence of the heavy chain can be fused with an expression tag (such as 6His) to form a fusion protein.
[0097] Once the relevant sequence is obtained, recombinant methods can be used to obtain it in large quantities. This is typically accomplished by cloning it into a vector, transferring it into cells, and then isolating the relevant sequence from the proliferated host cells using conventional methods. The biomolecules (nucleic acids, proteins, etc.) referred to in the present invention include biomolecules in isolated form.
[0098] Currently, DNA sequences encoding proteins of the present invention (or fragments thereof, or derivatives thereof) can be obtained entirely by chemical synthesis. This DNA sequence can then be introduced into various existing DNA molecules (or vectors) and cells known in the art. In addition, mutations can also be introduced into protein sequences of the present invention by chemical synthesis.
[0099] The present invention also relates to vectors comprising the above-mentioned appropriate DNA sequence and appropriate promoter or control sequence. These vectors can be used to transform appropriate host cells to enable them to express proteins.
[0100] Host cells can be prokaryotic cells, such as bacterial cells; lower eukaryotic cells, such as yeast cells; or higher eukaryotic cells, such as mammalian cells. Representative examples include: Escherichia coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells, such as yeast; insect cells such as Drosophila S2 or Sf9; and animal cells such as CHO, COS7, and 293 cells.
[0101] Transformation of host cells with recombinant DNA can be performed using conventional techniques well known to those skilled in the art. When the host is a prokaryotic organism such as Escherichia coli, competent cells capable of absorbing DNA can be harvested after the exponential growth phase and treated using the CaCl2 method, using procedures well known in the art. Another method is to use MgCl2. If desired, transformation can also be performed using electroporation. When the host is a eukaryotic organism, the following DNA transfection methods can be used: calcium phosphate coprecipitation, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.
[0102] The obtained transformants can be cultured using conventional methods to express the polypeptide encoded by the gene of the present invention. Depending on the host cell used, the culture medium used can be selected from various conventional culture media. Culture is carried out under conditions suitable for the growth of the host cells. After the host cells grow to an appropriate cell density, the selected promoter is induced using a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
[0103] The recombinant polypeptide in the above method can be expressed intracellularly, on the cell membrane, or secreted extracellularly. If necessary, the recombinant protein can be isolated and purified by various separation methods utilizing its physical, chemical, and other properties. These methods are well known to those skilled in the art. Examples of these methods include, but are not limited to, conventional renaturation treatment, treatment with a protein precipitant (salting out method), centrifugation, osmotic sterilization, ultrafiltration, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC), and various other liquid chromatography techniques and combinations of these methods.
[0104] The antibodies of the present invention may be used alone or in combination with a detectable label (for diagnostic purposes), a therapeutic agent, a PK (protein kinase) modifying moiety, or any combination of these.
[0105] Detectable labels for diagnostic purposes include, but are not limited to, fluorescent or luminescent labels, radioactive labels, MRI (magnetic resonance imaging) or CT (computed tomography) contrast agents, or enzymes capable of producing a detectable product.
[0106] Therapeutic agents that can be combined or coupled with the antibodies of the present invention include but are not limited to: 1. radionuclides; 2. biological toxins; 3. cytokines such as IL-2; 4. gold nanoparticles / nanorods; 5. viral particles; 6. liposomes; 7. nanomagnetic particles; 8. prodrug activating enzymes (for example, DT-diaphorase (DTD) or biphenyl hydrolase-like protein (BPHL)), etc.
[0107] Pharmaceutical composition
[0108] The present invention also provides a composition. Preferably, the composition is a pharmaceutical composition comprising the above-mentioned antibody, active fragment thereof, or fusion protein thereof, and a pharmaceutically acceptable carrier. Generally, these substances can be formulated in a non-toxic, inert, and pharmaceutically acceptable aqueous carrier medium, wherein the pH is generally about 5-8, preferably about 6-8, although the pH value may vary depending on the nature of the formulated substance and the condition to be treated. The formulated pharmaceutical composition can be administered by conventional routes, including (but not limited to): intraperitoneal, intravenous, or topical administration.
[0109] The pharmaceutical composition of the present invention contains a safe and effective amount (e.g., 0.001-99 wt%, preferably 0.01-90 wt%, more preferably 0.1-80 wt%) of the above-mentioned antibody of the present invention (or its conjugate) and a pharmaceutically acceptable carrier or excipient. Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. The pharmaceutical preparation should match the mode of administration. The pharmaceutical composition of the present invention can be prepared in the form of an injection, for example, using physiological saline or an aqueous solution containing glucose and other adjuvants by conventional methods. Pharmaceutical compositions such as injections and solutions are preferably manufactured under sterile conditions. The dosage of the active ingredient is a therapeutically effective amount, for example, about 10 micrograms / kg body weight to about 50 mg / kg body weight per day. In addition, the polypeptide of the present invention can also be used in conjunction with other therapeutic agents.
[0110] When using a pharmaceutical composition, a safe and effective amount of the immunoconjugate is administered to a mammal, wherein the safe and effective amount is generally at least about 10 μg / kg body weight, and in most cases does not exceed about 50 mg / kg body weight. Preferably, the dose is about 10 μg / kg body weight to about 10 mg / kg body weight. Of course, the specific dose should also take into account factors such as the route of administration and the patient's health status, which are all within the skill of a skilled physician.
[0111] Anti-CD22 antibodies
[0112] The present invention provides an anti-CD22 antibody that can specifically bind to CD22.
[0113] Specifically, the present invention provides an anti-CD22 nanobody, wherein the amino acid sequence of the complementarity determining region (CDR) of the VHH chain of the anti-CD22 nanobody is selected from the following group:
[0114] (1) CDR1 shown in SEQ ID NO: 13, CDR2 shown in SEQ ID NO: 14, and CDR3 shown in SEQ ID NO: 15;
[0115] (2) CDR1 shown in SEQ ID NO: 6, CDR2 shown in SEQ ID NO: 9, and CDR3 shown in SEQ ID NO: 10;
[0116] (3) CDR1 shown in SEQ ID NO: 6, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 12;
[0117] (4) CDR1 shown in SEQ ID NO: 6, CDR2 shown in SEQ ID NO: 7, and CDR3 shown in SEQ ID NO: 8; and
[0118] (5) CDR1 shown in SEQ ID NO: 6, CDR2 shown in SEQ ID NO: 7, and CDR3 shown in SEQ ID NO: 16.
[0119] In some embodiments of the present invention, any one of the amino acid sequences further comprises a derivative sequence that is optionally subjected to addition, deletion, modification and / or substitution of at least one (e.g., 1-3, preferably 1-2, more preferably 1) amino acid and can retain the ability to specifically bind to CD22.
[0120] Preferably, the VHH chain of the anti-CD22 nanobody has an amino acid sequence selected from SEQ ID NO: 1, 2, 3, 4 or 5.
[0121] The nanobody of the present invention has a high affinity for CD22. -9 M, preferably less than 10 -10 Binds to CD22 with an affinity (KD) of M or less.
[0122] The Nanobodies of the present invention share the advantages of Nanobodies, such as small molecular weight, rapid tissue penetration, high solubility and stability, high antigen-binding specificity, and weak immunogenicity. Furthermore, due to their small molecular weight, Nanobodies can recognize some invisible antigenic epitopes that monoclonal antibodies cannot. Furthermore, in the human body, Nanobodies may be less immunogenic than mouse antibodies. Therefore, using Nanobody sequences to construct antibody drugs or CAR-T drugs offers significant advantages over those constructed using mouse single-chain antibody sequences.
[0123] The CD22 nanobody of the present invention can be used to construct a CD22 nanobody drug for targeted treatment of B cell-related diseases or a CAR-T drug based on the CD22 nanobody sequence.
[0124] In another aspect of the present invention, an anti-CD22 antibody is also provided, which comprises one or more VHH chains of the above-mentioned anti-CD22 nanoantibodies, preferably, the VHH chain has the amino acid sequence shown in SEQ ID NO: 1, 2, 3, 4 or 5.
[0125] The main advantages of the present invention include:
[0126] 1) The antibodies of the present invention can specifically bind to CD22;
[0127] 2) The antibodies of the present invention have a high affinity for CD22;
[0128] 3) The CD22 antibody of the present invention is a nanobody, which has the advantages of small molecular weight, rapid tissue penetration, high solubility and stability, high antigen binding specificity, and weak immunogenicity.
[0129] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are by weight.
[0130] Experimental methods
[0131] 1. Antigen Preparation
[0132] 1) Genetically synthesize the extracellular segment of CD22 (20AA-687AA), add a human IgG1 Fc tag to the N-terminus, and add an enterokinase cleavage site between CD22 and Fc to remove the Fc tag; subclone into a eukaryotic expression vector to construct an antigen expression vector.
[0133] 2) Plasmid extraction was performed on the constructed CD22-Fc protein expression vector, and after transient transfection into 293 cells, the cells were cultured continuously for 8 days. The supernatant of the culture medium was collected by centrifugation and filtered through a 0.45 μm filter membrane. The filtrate was transferred to a sterile centrifuge tube, and the antibody was purified using a Protein A column.
[0134] 2. Antigen immunization of American camels
[0135] The CD22 protein prepared above was used to immunize one alpaca four times at multiple subcutaneous sites. The immunization schedule is shown in Table 1 below.
[0136] Table 1 Alpaca immunization program
[0137] 3. Detection of immune titer
[0138] 1) Collect 5 ml of peripheral blood and place the centrifuge tube containing the blood sample in a 37°C incubator for 1 hour; then transfer the blood sample to 4°C overnight;
[0139] 2) Transfer the serum to a new sterile centrifuge tube and centrifuge at 5000 rpm for 20 min; use ELISA to detect the immune titer.
[0140] 4. Biotin coupled to CD22 protein
[0141] 1) Prepare 1 mg of purified antigen in PBS buffer at a concentration of 1 mg / mL.
[0142] 2) Weigh NHS-biotin and dissolve it in DMSO to prepare 10 mM NHS-biotin.
[0143] 3) Add freshly prepared 10 mM NHS-biotin solution to the above protein sample, place the sample tube in a light-proof ziplock bag, and couple at 180 rpm at room temperature for 30 minutes.
[0144] 4) Replace with PBS to remove unlabeled biotin and store the labeled antigen protein at -80°C.
[0145] 5) Use ELISA to detect the biotin coupling effect.
[0146] 5. Single B Cell Isolation
[0147] 1) Collect 50 ml of peripheral blood and separate PBMCs using lymphocyte separation medium.
[0148] 2) PBMCs were divided into two parts, the first part had 5*10^5 cells as a negative control, and the second part had 1*10^7 cells.
[0149] 3) Add 20 μg / ml Biotin-coupled CD22 recombinant protein to the second cell suspension, incubate on ice for 1 hour, wash three times with pre-chilled PBS, and then incubate with APC-Streptavidin and FITC-Anti-Camelid VHH antibodies simultaneously, incubate on ice in the dark for 1 hour.
[0150] 4) Centrifuge at 500 x g and 4°C for 5 minutes and remove the supernatant containing the antibody.
[0151] 5) Wash three times with pre-cooled PBS.
[0152] 6) Add 500 μL of pre-chilled PBS buffer to resuspend the cell pellet and place on ice for single cell sorting.
[0153] 7) Prepare lysis buffer, take a 96-well PCR plate, add 4uL lysis buffer to each well; store on dry ice (prepare before sorting)
[0154] 8) Using a flow cytometer, sort FITC and APC double-positive single cells into 96-well plates (pre-added with lysis buffer). A total of two 96-well plates were separated for cloning nanobodies.
[0155] 6. Reverse Transcription of Single B Cell Lysates
[0156] 1) Remove the plate from dry ice or a -80°C freezer and thaw on ice.
[0157] 2) Set the temperature of the PCR instrument to 65°C.
[0158] 3) In a clean area, prepare reverse transcription mixture I (for one 96-well plate) according to Table 2 below.
[0159] Table 2 Reverse transcription mixture I configuration
[0160] 4) On ice, add 7 μL of Reverse Transcription Mix I to each well. Mix by gently pipetting.
[0161] 5) Cover the well and centrifuge at 400 x g and 4°C for 1 minute.
[0162] 6) Place the plate in a 65°C PCR instrument and incubate for 5 minutes.
[0163] 7) Immediately place the plate on ice to cool for 1-5 minutes.
[0164] 8) In a clean area, prepare reverse transcription mixture II according to Table 3 below (enough for one 96-well plate).
[0165] Table 3 Reverse transcription mixture II configuration
[0166] 9) On ice, add 7 μL of Reverse Transcription Mix II to each well and gently pipette to mix.
[0167] 10) Cover the well and centrifuge at 400 x g and 4°C for 1 minute.
[0168] 11) Place the plate in a PCR chamber and run the following program in Table 4:
[0169] Table 4 PCR reaction procedure
[0170] 12) After the PCR reaction is completed, add 10 μL of sterile ultrapure water to each well to dilute the cDNA sample; the diluted cDNA sample can be stored at -20°C or -80°C.
[0171] 7. Cloning of Single B Cell Antibody Sequences
[0172] 1) Prepare the PCR reaction mixture according to Table 5 below (the amount for one 96-well plate is used, and amplify to the required amount according to this ratio)
[0173] Table 5 PCR reaction system
[0174] 2) Take two 96-well plates for VHH cloning, mark them, and add 38uL of PCR reaction mixture to each well. Cover the wells and centrifuge at 400xg and 4°C for 1 minute.
[0175] 3) Take out the previously prepared cDNA sample plate, use an 8-channel pipette to take 4uL of cDNA sample and add it to the PCR reaction well, and pipette several times to mix.
[0176] 4) After configuring the PCR reaction system, set up the PCR instrument according to the program in Table 6 below:
[0177] Table 6 PCR reaction program
[0178] 5) After the PCR reaction is completed, the PCR product is analyzed using 1% agarose gel electrophoresis.
[0179] 6) Based on the agarose gel electrophoresis results, separate the target fragment with a molecular weight of 400 bp and perform sequencing analysis using the adapter sequence on the primer.
[0180] 8. Construction of recombinant antibody expression vector
[0181] The VHH antibody sequences analyzed above were synthesized separately and subcloned in tandem with human IgG1Fc into the expression vector Lenti-hIgG1-Fc2 (vector schematic shown in Figure 1). After the vector was sequenced and verified to be correct, an endotoxin-free plasmid was prepared using the Qiagen Plasmid Maxi Kit.
[0182] 9. Expression of Recombinant Antibodies
[0183] 1) Remove LVTransm transfection reagent and the antibody expression vector Lenti-hIgG1-Fc2 from the refrigerator. Thaw at room temperature and mix thoroughly by pipetting up and down. Remove the PBS buffer and warm it to room temperature. Transfer 500 μl of PBS to one well of a 24-well plate, add 4 μg of Lenti-hIgG1-Fc2, and mix thoroughly by pipetting up and down. Then, add 12 μl of LVTransm and immediately mix by pipetting up and down. Let stand at room temperature for 10 minutes. This mixture is referred to as the DNA / LVTransm complex.
[0184] 2) Add 532 μl of the DNA / LVTransm complex to 1.5 mL of 293F cells and shake gently to mix thoroughly. Place the cells in a 37°C, 5% CO2 incubator at 130 RPM for 6-8 hours, then add 1.5 mL of fresh FreeStyle TM 293 culture medium and place the cells back into the incubator for continued culture.
[0185] 3) After 3 days of continuous culture, the culture supernatant was collected by centrifugation, filtered through a 0.45 μm filter membrane, and the filtrate was transferred to a sterile centrifuge tube for subsequent flow cytometry and ELISA detection.
[0186] 10. Flow cytometry detection of the binding of recombinant antibodies to target proteins
[0187] 1) CHO-K1 and CHO-K1-CD22 cell lines were revived from liquid nitrogen and adjusted to the logarithmic growth phase using F12K and 10% FBS complete medium.
[0188] 2) Divide the two types of cells into several portions, with the number of cells in each portion being 5*10^5 cells.
[0189] 3) Incubate the target cells with the expressed antibodies, mix thoroughly, and incubate at room temperature for 1 hour.
[0190] 4) Centrifuge at 800 x g for 5 minutes at room temperature, remove the supernatant containing the antibody, and wash the cells three times with PBS.
[0191] 5) Add 1 μL of PE-labeled Anti-human IgG, mix thoroughly, and incubate at room temperature in the dark for 30 minutes;
[0192] 6) Centrifuge at 800 x g for 5 minutes at room temperature, remove the supernatant containing the secondary antibody, and wash the cells three times with PBS;
[0193] 7) Resuspend the cells in 500 μL PBS and perform flow cytometry analysis.
[0194] 11. Expression and purification of recombinant antibodies
[0195] 1) Remove LVTransm transfection reagent and single-chain antibody expression vector from the refrigerator. Thaw at room temperature and mix thoroughly by pipetting up and down. Remove PBS buffer and warm to room temperature. Dispense 2 mL of PBS into each well of a 6-well plate and add 130 μg of Lenti-hIgG1-Fc2. Mix thoroughly by pipetting up and down. Then, add 400 μL of LVTransm and immediately mix by pipetting up and down. Let stand at room temperature for 10 minutes.
[0196] 2) Add the DNA / LVTransm complex to 50 mL of 293F cells and shake gently to mix thoroughly. Place the cells in a 37°C, 5% CO2 incubator at 130 RPM for 6-8 hours, then add 50 mL of fresh FreeStyle TM 293 culture medium and place the cells back into the incubator for continued culture.
[0197] 3) After 7 days of continuous culture, the culture supernatant was collected by centrifugation, filtered through a 0.45 μm filter membrane, and the filtrate was transferred to a sterile centrifuge tube. The antibody was purified using a Protein A column.
[0198] 12. Recombinant Antibody Affinity Testing
[0199] The CD22-Fc recombinant protein was immobilized on a CM5 chip using 10 mM Acetate buffer, and the prepared nanobodies were used as the mobile phase to detect the binding ability of the candidate nanobodies to the target protein CD22.
[0200] Example 1 Single B cell protocol for preparation and purification of CD22 nanobodies
[0201] 1.1 Immune titer ELISA test
[0202] Serum was isolated from the immunized alpaca, and limited dilution was performed according to the dilution gradient shown in Table 7. ELISA assays were performed on 96-well plates pre-coated with different concentrations of antigen.
[0203] Results: As shown in Table 7, the ELISA test results showed that after three immunizations, the immune titer was good.
[0204] Table 7 Immune serum titer test results
[0205] After one pulse immunization, 50 mL of peripheral blood was collected 3 days later for single B cell antibody sequence cloning.
[0206] 1.2 Isolation of single B cells
[0207] Peripheral blood was collected from CD22-immunized alpacas, and PBMCs were isolated. PBMCs were incubated with Biotin-conjugated CD22 recombinant protein, washed three times with pre-chilled PBS, and then incubated with APC-Streptavidin and FITC-Anti-Camelid VHH antibodies. After incubation, single cells positive for FITC and APC were sorted by flow cytometry into 96-well plates (pre-loaded with lysis buffer). Two 96-well plates were used for cloning nanobodies.
[0208] Results: The results of peripheral blood PBMC sorting are shown in Figure 2. The sorted cells are the cells in gate P4 in the flow cytometry chart (Figure 2).
[0209] 1.3 Cloning of single B cell antibody sequences
[0210] Take the sorted 96-well plate, extract RNA from a single B cell in each well, reverse it to cDNA, and perform PCR using nanobody amplification primers. After the products are separated by agarose gel electrophoresis, the PCR products of about 400 bp are separated and Sanger sequencing is performed to obtain the sequence information of the nanobody coding region. The sequence obtained by sequencing is subjected to gene synthesis and subcloned into an antibody expression vector with human IgG1Fc.
[0211] 1.4 Expression and detection of nanobodies
[0212] The sequence obtained by sequencing in Example 1.3 was synthesized and subcloned into an antibody expression vector carrying human IgG1 Fc. After the constructed nanobody was expressed, the binding of the recombinant antibody to the target protein was detected by flow cytometry using Experimental Method 10.
[0213] Results: The flow cytometry results are shown in Figure 3. Based on the flow cytometry results, clone S190177-C10 was selected for antibody expression, purification, and affinity testing.
[0214] 1.5 Quantitative affinity detection
[0215] The affinity of the antibody was determined using CD22-Fc recombinant protein by experimental method 12.
[0216] Results: The affinity test results are shown in Table 8.
[0217] Table 8 Antibody affinity test results
[0218] This example demonstrates that the antibody S190177-C10 of the present invention has a high affinity for CD22.
[0219] Example 2 Yeast display library screening scheme Preparation and purification of CD22 nanobody
[0220] 2.1 Immune titer ELISA test
[0221] The experimental method was the same as that in Example 1.1. Three days after the shock immunization, 100 mL of peripheral blood was collected for the construction of the yeast display library.
[0222] 2.2 Amplification of VHH fragments
[0223] Total RNA was collected from peripheral blood and reverse transcribed into cDNA. Two rounds of PCR were performed using nanobody amplification primers. PCR products were analyzed by agarose gel electrophoresis. The first round of PCR yielded PCR bands of approximately 1000 bp and 750 bp, respectively. The 750 bp fragment was recovered from the gel and used as template for the second round of PCR. The second round of PCR yielded a 450 bp band, representing the VHH fragment.
[0224] 2.3 Diversity analysis of yeast display libraries
[0225] Twenty yeast clones were randomly selected for sequencing to analyze the diversity of the constructed yeast display library. Sequencing results showed that the yeast display library was diverse, with a library capacity of 8.6×10^6.
[0226] 2.4 Flow cytometry after the first separation of streptavidin magnetic beads
[0227] After induction of expression in the electroporated yeast library, the cells were fully bound to Biotin-CD22-Fc protein and magnetically separated using streptavidin magnetic beads. The separated yeast cells were cultured and, after induction of expression, analyzed by flow cytometry. The cells were incubated with Biotin-CD22-Fc2 for 1 hour, using PE-streptavidin as a secondary antibody, and then analyzed by flow cytometry.
[0228] According to the flow cytometry results, Biotin-CD22-Fc was used for magnetic sorting of yeast positive clones with good sorting effect. After the first round of sorting, the yeast cells were cultured and induced to express, and then a second round of sorting was performed.
[0229] 2.5 Flow cytometry after the second sorting of streptavidin magnetic beads
[0230] The products from the first round of magnetic separation were fully bound to Biotin-CD22-Fc protein and then subjected to a second round of magnetic separation using streptavidin magnetic beads. A portion of the sorted yeast cells was directly plated onto PAD plates for single clone selection and verification; a portion was cultured for flow cytometry analysis. After incubation with Biotin-CD22-Fc2 for 1 hour, PE Streptavidin was used as the secondary antibody. Flow cytometry analysis was performed after completion of the incubation.
[0231] According to the flow cytometry results, after the second magnetic separation, the yeast positive rate was 99.289%, and the positive clones were significantly enriched. The separation products were directly coated on PAD plates, and single clones were selected for flow cytometry.
[0232] 2.6 Yeast display single clone detection and sequencing
[0233] The yeast positive clones obtained from the two sortings were directly coated on PAD plates, single clones were selected, induced for 24 hours, and fully bound to Biotin-CD22-Fc protein for flow cytometry analysis.
[0234] Yeast monoclonal clones were selected and inoculated into 96-well plates. Expression was induced for 24 hours. The clones were then incubated with Biotin-CD22-Fc2 for 1 hour, using PE-Streptavidin as a secondary antibody. Flow cytometry analysis revealed that all selected clones bound to Biotin-CD22-Fc2. Based on the flow cytometry results of yeast monoclonal clones, genomic DNA was extracted from clones positive for CD22-Fc2 binding, and the antibody sequence was obtained by PCR. Based on the sequencing results of the PCR product, the VHH antibody sequence was subcloned into Lenti-hIgG1-Fc2 to construct a eukaryotic expression vector.
[0235] 2.7 Flow cytometry detection of eukaryotic expression of CD22 nanoantibodies
[0236] The results of eukaryotic expression flow cytometry are shown in Figure 4. According to the FACS detection results, LAB190216-D-1-C8, D-2-D4, and 22-C9 can bind to CHO-K1-CD22 recombinant cells, but not to CHO-K1.
[0237] 2.8 Flow cytometry detection of eukaryotic expression of CD22 nanoantibodies
[0238] The D-1-C8 and D-2-D4 antibodies were selected for affinity testing. The results are shown in Table 9.
[0239] Table 9 Antibody affinity test results
[0240] Antibody sequence
[0241] The VHH sequences of the Nanobodies of the present invention are shown in Table 10, and the CDR region sequences of the VHH chains of the respective antibodies are shown in Table 11.
[0242] Table 10 Nanobody VHH chain sequences of the present invention
[0243] Among them, the underlined part of the sequence is the CDR region, and the VHH sequence structure is FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
[0244] Table 11 CDR region sequences of each antibody VHH chain
[0245] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.
Claims
1. An anti-CD22 nanobody, characterized in that The amino acid sequence of the complementary determining region CDR of the VHH chain of the anti-CD22 nanobody is selected from the following group: (1) CDR1 shown in SEQ ID NO: 13, CDR2 shown in SEQ ID NO: 14, and CDR3 shown in SEQ ID NO: 15; (2) CDR1 shown in SEQ ID NO:6, CDR2 shown in SEQ ID NO:9, and CDR3 shown in SEQ ID NO:10; (3) CDR1 shown in SEQ ID NO:6, CDR2 shown in SEQ ID NO:11, and CDR3 shown in SEQ ID NO:12; (4) CDR1 shown in SEQ ID NO:6, CDR2 shown in SEQ ID NO:7, and CDR3 shown in SEQ ID NO:8; and (5) CDR1 shown in SEQ ID NO:6, CDR2 shown in SEQ ID NO:7, and CDR3 shown in SEQ ID NO:
16.
2. The anti-CD22 nanobody according to claim 1, characterized in that The anti-CD22 nano antibodies include humanized antibodies, camel-derived antibodies, and chimeric antibodies.
3. The anti-CD22 nanobody according to claim 1, characterized in that The VHH chain amino acid sequence of the anti-CD22 nanobody has ≥85%, ≥90%, ≥95%, ≥96%, ≥97%, ≥98%, or ≥99% sequence identity with the amino acid sequence shown in SEQ ID NO: 1, 2, 3, 4 or 5.
4. The anti-CD22 nanobody according to claim 1, characterized in that The VHH chain of the anti-CD22 nanobody has an amino acid sequence selected from SEQ ID NO: 1, 2, 3, 4 or 5.
5. An anti-CD22 chimeric antigen receptor (CAR), characterized in that The chimeric antigen receptor comprises an antigen binding domain, which comprises one or more VHH chains of the anti-CD22 Nanobody according to claim 1.
6. A polynucleotide, characterized in that The polynucleotide encodes a protein selected from the group consisting of an anti-CD22 nanobody as described in claim 1, or an anti-CD22 chimeric antigen receptor as described in claim 5.
7. An expression vector, characterized in that: The expression vector contains the polynucleotide according to claim 6.
8. A host cell, characterized in that The host cell contains the expression vector according to claim 7, or the polynucleotide according to claim 6 is integrated into its genome.
9. A method for producing anti-CD22 nanobodies, characterized in that: The method comprises the steps of: (a) culturing the host cell according to claim 8 under conditions suitable for the production of nanobodies, thereby obtaining a culture containing the anti-CD22 nanobody; (b) separating and / or recovering said anti-CD22 Nanobody from said culture; and (c) Optionally, purifying and / or modifying the anti-CD22 Nanobody obtained in step (b).
10. An immunoconjugate, comprising: (a) an anti-CD22 Nanobody as described in any one of claims 1 to 4, or a chimeric antigen receptor as described in claim 5; and (b) a conjugated moiety selected from the group consisting of a detectable marker, a drug, an enzyme, a cytokine, a nanomagnetic particle, a viral coat protein or a VLP, or a combination thereof.
11. A pharmaceutical composition, comprising: (i) an anti-CD22 Nanobody as described in any one of claims 1 to 4, a chimeric antigen receptor as described in claim 5, or an expression vector as described in claim 7, or a host cell as described in claim 8, or an immunoconjugate as described in claim 10; and (ii) a pharmaceutically acceptable carrier.
12. An anti-CD22 nanobody as described in any one of claims 1 to 4, or a chimeric antigen receptor as described in claim 5, or an expression vector as described in claim 7, or a host cell as described in claim 8, or an immunoconjugate as described in claim 10, for preparing a medicament for preventing and / or treating a CD22-related disease.
13. The anti-CD22 nanobody, chimeric antigen receptor, expression vector, host cell, or immunoconjugate used as claimed in claim 12, characterized in that: The CD22-related disease is cancer or autoimmune disease.
14. The anti-CD22 nanobody, chimeric antigen receptor, expression vector, host cell, or immunoconjugate for use as claimed in claim 12, characterized in that: The CD22-related disease is acute B-lymphocytic leukemia (B-ALL), B-cell lymphoma, or a combination thereof.
15. An anti-CD22 nanobody as described in any one of claims 1 to 4 or an immunoconjugate as described in claim 10 for use in the preparation of a reagent for detecting CD22.
Citation Information
Patent Citations
Screening method of CD22 nano antibody
CN112724254A
CD22 nano antibody, separated nucleic acid molecule, pharmaceutical composition and application thereof
CN112830970A
Anti-CD22 nano antibody and application thereof
CN115925948A
Anti-CD22 nano antibody as well as preparation method and application thereof
CN115960233A
CD22 binding molecules and uses thereof
WO2022012682A1
